Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Isotechnika Pharma Inc IPHAF

Healthcare Biotechnology


GREY:IPHAF - Post by User

Isotechnika Pharma Inc
Bullboard Posts
User Avatar Image
(2)
•••
Comment by labumbaon Mar 08, 2006 10:17pm
325 Views
Post# 10486669

RE: new presentation / slide 42

RE: new presentation / slide 42I haven't got through the presentation yet....I am sure it is a head-to-head trial with CSA seeing CSA is widely used in Europe for Transplant and psoriasis indications. I think the 5 mg/kg bid of CSA is part of dosing scale for organ transplants and it should be lower dose for psoriasis as 1.25 mg suggested.
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities